Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | CTSG | P08311 | 1/20 | 0.35 |
| ▸ | CTRC | Q99895 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17213445 | 0.87 | PLA2G7 (0.47) | PLA2G7HDAC6ALDH1A1RECQLNR1H2 | |
| SCHEMBL13204644 | 0.85 | MGLL (0.47) | PLA2G7HDAC6ALDH1A1NR1H2CYP19A1 | |
| SCHEMBL414553 | 0.84 | F2 (0.48) | PLA2G7HDAC6ALDH1A1RECQLMEN1 | |
| SCHEMBL11264830 | 0.84 | MGLL (0.50) | PLA2G7ALDH1A1CYP19A1 | |
| SCHEMBL11252578 | 0.84 | MGLL (0.50) | PLA2G7ALDH1A1CYP19A1 | |
| SCHEMBL30372493 | 0.84 | MGLL (0.50) | PLA2G7ALDH1A1CYP19A1 | |
| SCHEMBL24738599 | 0.80 | PLA2G7 (0.49) | PLA2G7HDAC6ALDH1A1RECQLMEN1 | |
| SCHEMBL7291993 | 0.80 | PLA2G7 (0.49) | PLA2G7HDAC6ALDH1A1RECQLMEN1 | |
| SCHEMBL22702280 | 0.80 | PLA2G7 (0.49) | PLA2G7HDAC6ALDH1A1RECQLMEN1 | |
| SCHEMBL13853160 | 0.80 | HDAC6 (0.50) | PLA2G7HDAC6F2ELANECTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112593251-B | Electrochemical reaction device | 株式会社东芝 | 2024-02-09 | — | — | CN | disclosed |
| CN-116194211-A | Method and apparatus for producing ammonia | 日产化学株式会社 | 2023-05-30 | — | — | CN | disclosed |
| EP-2931280-B1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS INC (US) | 2018-02-14 | — | — | EP | disclosed |
| US-20160304533-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-9340532-B2 | Methods and compositions for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-9139609-B2 | C-4″ position substituted macrolide derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| WO-2014093988-A2 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| EP-1778008-A4 | NOVEL SOLID COMPOSITIONS FOR DISINFECTING WATER | BROMINE COMPOUNDS LTD (IL) | 2009-08-26 | — | — | EP | disclosed |
| US-20080038303-A1 | Novel Solid Compositions for Disinfected Water | BROMINE COMPOUNDS LTD. (IL) | 2008-02-14 | — | — | US | disclosed |
| EP-1778008-A2 | NOVEL SOLID COMPOSITIONS FOR DISINFECTING WATER | Bromine Compounds Ltd. (IL) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006006155-A2 | NOVEL SOLID COMPOSITIONS FOR DISINFECTING WATER | BROMINE COMPOUNDS LTD. (IL) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | CNKSR1, CAMKK1, CAMKK2 | PLA2G7 1691/4885HDAC6 2725/4885ALDH1A1 4764/4885 |
| US-20160304533-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 | CNKSR1, CAMKK1, CNR1 | PLA2G7 1406/4885HDAC6 1690/4885ALDH1A1 4731/4885 |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MRPL21, MRPS34, MRPL37 | PLA2G7 4284/4885HDAC6 783/4885ALDH1A1 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.